Revenue: US$5.18m (down 9.3% from 3Q 2023). Net loss: US$535.0k (loss narrowed by 75% from 3Q 2023). US$0.091 loss per share ...

Psychemedics ( (PMD) ) has released its Q3 earnings. Here is a breakdown of the information Psychemedics presented to its investors.

DALLAS, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), the world’s leading provider of hair testing for drugs of abuse, today announced financial results for the third ...

DALLAS (AP) — DALLAS (AP) — Psychemedics Corp. (PMD) on Tuesday reported a loss of $500,000 in its third quarter. On a per-share basis, the Dallas-based company said it had a loss of 9 cents. The drug ...

Psychemedics (NASDAQ:PMD) just reported results for the fourth quarter of 2023. Psychemedics reported earnings per share of -86 cents. The company reported revenue of $5.00 million. InvestorPlace ...

DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever ...

DALLAS, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD), a global leader in hair testing for drugs of abuse, is excited to announce the release of its first-ever ...

Dimensional Fund Advisors LP cut its holdings in Psychemedics Co. (NASDAQ:PMD – Free Report) by 37.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine ...